Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control

Monday, September 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies has launched the Agilent 4150 and 4200 TapeStationDx systems, along with TapeStationDx software, aimed at improving quality control for DNA and RNA samples in clinical next-generation sequencing. These systems are CE-IVD labeled, ensuring they meet regulatory standards for clinical use. This expansion enhances Agilent's automated electrophoresis portfolio.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of new TapeStationDx systems enhances quality control.
  • CE-IVD labeling indicates compliance with clinical standards.
  • Supports next-generation sequencing in clinical labs.

Full Press Release Details

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 4150 TapeStationDx system, Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending the company's automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing

Frequently Asked Questions

What are the new systems launched by Agilent?

Agilent launched the 4150 and 4200 TapeStationDx systems.

What is the purpose of the TapeStationDx systems?

They are designed for quality control of DNA and RNA samples.

What regulatory approval do the systems have?

The systems are CE-IVD labeled for clinical use.

What technology do the systems support?

They support next-generation sequencing in clinical laboratories.

ShareAdd on Google
Tags: A Viatris Investor Conferences Healthcare Agilent TapeStationDx clinical NGS quality control DNA
Last updated: Sep 21, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk